Open access
Open access
Powered by Google Translator Translator

Endocrinology (all articles)

Clinical Trial Update | Mesenteric defects closure in bariatric surgery cuts reoperation rate due to bowel obstruction

29 May, 2023 | 10:49h | UTC

Long-term Safety and Efficacy of Closure of Mesenteric Defects in Laparoscopic Gastric Bypass Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

See also: Visual Abstract

 

A pragmatic approach to the management of menopause

25 May, 2023 | 11:30h | UTC

A pragmatic approach to the management of menopause – Canadian Medical Association Journal

News Release: Managing menopause: Hormone therapy is back – Canadian Medical Association Journal

 

Review | Exercise training and revascularization in the management of symptomatic peripheral artery disease

25 May, 2023 | 11:23h | UTC

Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease – JACC: Basic to Translational Science

 

Commentary on Twitter

 

Graves’ disease in children: an update

25 May, 2023 | 11:18h | UTC

Graves’ Disease in Children: An Update – Clinical Medicine Insights: Endocrinology and Diabetes

 

Guidelines on the diagnosis and treatment of foot infection in persons with diabetes

24 May, 2023 | 13:30h | UTC

Guidelines on the diagnosis and treatment of foot infection in persons with diabetes – International Working Group on the Diabetic Foot

 

RCT | Spironolactone enhances acne outcomes and offers a viable alternative to oral antibiotics

24 May, 2023 | 13:27h | UTC

Summary: The SAFA (Spironolactone for Adult Female Acne) trial was a multicenter, phase 3, double-blind, randomized controlled trial in England and Wales and evaluated the efficacy of spironolactone for treating adult women with acne vulgaris. A total of 410 women, aged ≥18 years and suffering from facial acne for a minimum of six months, were randomly assigned to receive either 50 mg/day of spironolactone or a placebo, increasing to 100 mg/day until week 24.

The primary outcome was measured by the Acne-Specific Quality of Life (Acne-QoL) symptom subscale score at week 12 and 24. The trial demonstrated that spironolactone improved Acne-QoL scores more effectively than the placebo, particularly at week 24. Additionally, more participants in the spironolactone group reported acne improvement, and treatment success was significantly higher in this group at week 12. Mild side effects, notably headaches, were more common in the spironolactone group.

The findings from the SAFA trial highlight spironolactone’s effectiveness, safety, and tolerability in treating adult women with acne vulgaris, suggesting it is a viable alternative to long-term antibiotic treatments. Future research is proposed on higher initial dosages of spironolactone, and its effects on different subgroups like patients with different ages, body mass index, and ethnicity.

Article: Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial – The BMJ

Editorial: What do we know about prescribing spironolactone for acne? – The BMJ

News Release: Non-antibiotic treatment for women with persistent acne shown to be effective – University of Southhampton

 

Review | Glycemic management in people with diabetes on peritoneal dialysis

24 May, 2023 | 13:04h | UTC

Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis – Kidney International Reports

 

Commentary on Twitter (thread – click for more)

 

Opinion Video | Questioning the reliability of nutrition science

23 May, 2023 | 13:02h | UTC

Nutrition science is entirely unreliable | Don’t trust the New York Times Well section – By Dr Vinay Prasad

 

AHA Statement | Addressing diabetes and atherosclerosis in Asian American adults: insights, management, future steps

22 May, 2023 | 13:42h | UTC

Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association – Circulation

News Release: Culture, diet, economic factors and more affect CVD risk among Asian Americans – American Heart Association

Commentary: The epidemic of diabetes and atherosclerotic cardiovascular disease in Asian Americans- Our voices must be heard! – American Heart Association

Commentary: Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says – TCTMD

 

Commentary on Twitter

 

Underdiagnosis of primary aldosteronism: a review of screening and detection

22 May, 2023 | 13:40h | UTC

Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection – American Journal of Kidney Diseases

 

Commentary on Twitter

 

RCT | Once-weekly insulin icodec shows non-inferiority to daily insulin glargine in type 2 diabetes patients

18 May, 2023 | 13:48h | UTC

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

 

WHO advises not to use non-sugar sweeteners for weight control in newly released guideline

16 May, 2023 | 15:04h | UTC

News Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization

WHO Guideline: Use of non-sugar sweeteners – World Health Organization

Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization

 

Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women

15 May, 2023 | 13:23h | UTC

Recommendations on screening for primary prevention of fragility fractures – Canadian Medical Association Journal

Related USPSTF Statement: Screening Osteoporosis to Prevent Fractures

 

RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients

15 May, 2023 | 13:07h | UTC

Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)

 

Commentary on Twitter

 

M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients

15 May, 2023 | 12:52h | UTC

Additional effects of exercise to hypocaloric diet on body weight, body composition, glycaemic control and cardio-respiratory fitness in adults with overweight or obesity and type 2 diabetes: A systematic review and meta-analysis – Diabetic Medicine

 

Endocrinopathies from checkpoint inhibitors: incidence, outcomes, and management

12 May, 2023 | 13:36h | UTC

Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management – Cleveland Clinic Journal of Medicine

Related:

Diagnostic criteria and management recommendations for immune related endocrinopathies following immune checkpoint inhibitor therapy for cancer – Endocrine Connections

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society – Endocrinology and Metabolism

The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors – Deutsches Ärzteblatt International

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports – Clinical Diabetes and Endocrinology

 

Aspirin for primary prevention of cardiovascular disease: what do the current USPSTF guidelines say?

11 May, 2023 | 12:11h | UTC

Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say? – Cleveland Clinic Journal of Medicine

Editorial: Aspirin in primary prevention of cardiovascular events: Key questions remain – Cleveland Clinic Journal of Medicine

Original Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.

Related Randomized Trials:

Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease

Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes

Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Related Meta-Analysis:

Meta-Analysis: Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events

Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups – BMC Medicine

Related Opinions:

Aspirin for Primary Prevention: Is This the End of the Road?

Evidence evolving on aspirin as prevention – ACP Internist

#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders

 

Review | Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery

11 May, 2023 | 11:54h | UTC

Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery – Perioperative Medicine

Related:

Current practice in the perioperative management of patients with diabetes mellitus: a narrative review – British Journal of Anaesthesia

Guideline Summary: New guidance on the perioperative management of diabetes.

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Recent advances in diabetes treatments and their perioperative implications – Current Opinion in Anesthesiology

Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes – Anesthesiology

 

FDA warns of use of selective androgen receptor modulators (SARMs) among teens, young adults

10 May, 2023 | 16:00h | UTC

FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults – U.S. Food & Drug Administration

Commentaries:

FDA issues warning for bodybuilding products marketed to teens, young adults – AAP News

Young Men Are Using Banned ‘SARM’ Supplements to Bulk Up, With Harmful Results – HealthDay

Guideline | Use of basal insulin in the management of adults with type 2 diabetes

10 May, 2023 | 15:30h | UTC

Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline – Journal of Diabetes

Related: Guideline | ADA 2023 Standards of Medical Care in Diabetes.

 

Consensus Statement | Comprehensive type 2 diabetes management algorithm – 2023 update

9 May, 2023 | 15:10h | UTC

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update – Endocrine Practice

Related: Guideline | ADA 2023 Standards of Medical Care in Diabetes

 

Consensus | Addressing stigma/bias in diagnosing, managing obesity-based chronic disease, and evaluating determinants of severity

9 May, 2023 | 15:08h | UTC

American Association of Clinical Endocrinology Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity – Endocrine Practice

 

RCT | Early treatment of gestational diabetes slightly lowers risk of adverse neonatal outcomes

9 May, 2023 | 14:55h | UTC

Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Early treatment of gestational diabetes for those at higher risk beneficial, study finds – Western Sidney University

 

Review | Syndrome of inappropriate antidiuresis: from pathophysiology to management

9 May, 2023 | 14:37h | UTC

Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management – Endocrine Reviews

Metformin: update on mechanisms of action and repurposing potential

8 May, 2023 | 13:05h | UTC

Metformin: update on mechanisms of action and repurposing potential – Nature Reviews Endocrinology (if the link is paywalled, try this one in PMC)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.